+86-576-88205808
Ubrogepant, also known as MK-1602, is a potent and selective oral calcitonin gene-related peptide (CGRP) receptor antagonist. Ubrogepant has completed Phase II clinical trials for acute treatment of migraines.
Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.
Address:Economic Developed Zone of Taizhou Zhejiang China